Amgen Inc.
$252.25B- Market cap
- $206.78B
- Debt
- +$54.60B
- Cash
- −$9.13B
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $206.78B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: AMGN stock price vs JNJ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JNJ's multiple
Needs JNJ P/E.
Implied fair value · at AMGN's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
Johnson & Johnson · implied price per share
Bear
$76.44
Base
$92.02
Bull
$112.30
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN can sustain its high ROIC and faster revenue growth while managing leverage, then accumulate on pullbacks toward the P/E-implied level (~$309.76) because EV-based multiples already show relative value and downside to the P/E-implied price is ~11.7%; if you believe the leverage (Debt/Equity 6.8x) or lower net margin will weigh on earnings, then avoid initiating new positions or consider trimming exposure.
AMGN trades above its P/E-implied price (current $350.95 vs implied $309.76, -11.7%), driven by a higher reported P/E versus JNJ despite cheaper EV multiples. The market is valuing AMGN at a P/E premium (24.7x vs JNJ 21.8x) even though EV/EBITDA and EV/Revenue show relative value.
Supporting Metrics